

OncoTherapy Science, Inc.

January 16, 2020

Announcement of milestone payment for the progress of Phase III clinical trial  
of the cancer-specific peptide vaccine S-588410

OncoTherapy Science, Inc. (President & CEO : Jae-Hyun Park ; hereinafter, “OncoTherapy” ) announces that OncoTherapy has received notification of the achievement of a milestone from Shionogi & Co., Ltd. (Head office: Chuo-ku, Osaka-city, Osaka, President & CEO: Isao Teshirogi) , pursuant to the agreement between the both parties, in connection with the progress of the Phase III clinical trial of the cancer-specific peptide vaccine S-588410 for esophageal cancer which OncoTherapy has out-licensed to Shionogi.